Under the Symbol:
Rigrodsky & Long, P.A. Files Class Action Suit Against Array BioPharma Inc.
Wednesday, July 10, 2019 10:35 AM
WILMINGTON, DE / ACCESSWIRE / July 10, 2019 / Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of Array BioPharma Inc. (“Array”) (NASDAQ GM: ARRY) common stock in connection with the proposed acquisition of Array by Pfizer Inc. (“Pfizer”) and Arlington Acquisition Sub Inc. (“Merger Sub”) announced on June 17, 2019 (the “Complaint”). The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Array, its Board of Directors (the “Board”), Pfizer, and Merger Sub, is captioned Kent v. Array BioPharma Inc., Case No. 1:19-cv-01248 (D. Del.).
If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, DE 19801, by telephone at (888) 969-4242, by e-mail at [email protected], or at http://rigrodskylong.com/contact-us/.
On June 14, 2019, Array entered into an agreement and plan of merger (the “Merger Agreement”) with Pfizer and Merger Sub. Pursuant to the terms of the Merger Agreement, shareholders of Array will receive $48.00 per share in cash (the “Proposed Transaction”).
Among other things, the Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, defendants issued materially incomplete disclosures in a solicitation statement (the “Solicitation Statement”) filed with the United States Securities and Exchange Commission. The Complaint alleges that the Solicitation Statement omits material information with respect to, among other things, Array’s financial projections and the analyses performed by Array’s financial advisor. The Complaint seeks injunctive and equitable relief and damages on behalf of holders of Array common stock.
If you wish to serve as lead plaintiff, you must move the Court no later than September 9, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.
Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
Fax: (302) 654-7530
SOURCE: Rigrodsky & Long, P.A.